Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Work
Year: 2014
Type: article
Source: The Lancet Oncology
Institutions Guangdong General Hospital, Guangdong Academy of Medical Sciences, Shanghai Pulmonary Hospital, Xiangya Hospital Central South University, Central South University +13 more
Cites: 35
Cited by: 1,871
Related to: 10
FWCI: 173.2
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed